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ABSTRACT
Objective To evaluate QRISK2 and Framingham
cardiovascular disease (CVD) risk scores in a tri-ethnic
UK population.
Design Cohort study.
Setting West London.
Participants Randomly selected from primary care
lists. Follow-up data were available for 87% of traced
participants, comprising 1866 white Europeans,
1377 South Asians, and 578 African Caribbeans, aged
40–69 years at baseline (1998–1991).
Main outcome measures First CVD events:
myocardial infarction, coronary revascularisation, angina,
transient ischaemic attack or stroke reported by
participant, primary care or hospital records or death
certiﬁcate.
Results During follow-up, 387 CVD events occurred in
men (14%) and 78 in women (8%). Both scores
underestimated risk in European and South Asian
women (ratio of predicted to observed risk: European
women: QRISK2: 0.73, Framingham: 0.73; South Asian
women: QRISK2: 0.52, Framingham: 0.43). In African
Caribbeans, Framingham over-predicted in men and
women and QRISK2 over-predicted in women.
Framingham classiﬁed 28% of participants as high risk,
predicting 54% of all such events. QRISK2 classiﬁed
19% as high risk, predicting 42% of all such events.
Both scores performed poorly in identifying high risk
African Caribbeans; QRISK2 and Framingham identiﬁed
as high risk only 10% and 24% of those who
experienced events.
Conclusions Neither score performed consistently well
in all ethnic groups. Further validation of QRISK2 in
other multi-ethnic datasets, and better methods for
identifying high risk African Caribbeans and South Asian
women, are required.
INTRODUCTION
Risk prediction is a cornerstone of strategies
for prevention of cardiovascular disease (CVD).1 2
The last 30 years have seen the derivation and
modiﬁcation of numerous risk calculators.3–10
People of South Asian origin experience greater
risk than people of European origins, while in the
UK, people of African Caribbean origin have lower
risks of coronary heart disease (CHD), but higher
risks of stroke.11 Earlier UK studies reported that
the Framingham score (developed in a largely
white US community) predicted no difference in
risk between South Asians and white Europeans
either with diabetes or in the general population in
terms of CVD mortality12 and CHD and stroke
risk.13 14 The Framingham score has been criticised
for lack of socioeconomic adjustment, overestimat-
ing risk in low risk and afﬂuent populations, while
underestimating risk in less afﬂuent
populations.15–17
More recently, QRISK2, including adjustment
for deprivation and ethnicity, has undergone
internal and external validation using UK primary
care datasets.4 18 However, the performance of
QRISK2 in ethnic minorities was not reported sep-
arately.18 Earlier guidelines from the UK National
Institute for Health and Care Excellence (NICE)
recommended lower risk thresholds for South
Asian men (but not women), by multiplying the
Framingham risk scores by 1.4,3 19 although this
approach remains untested. In 2010 NICE recom-
mended that the Framingham risk equation would
no longer be recommended for CVD risk assess-
ment, but that it could be considered together with
other risk scores such as QRISK2. We evaluated the
performance of Framingham3 19) and QRISK2
scores as predictors of CVD outcomes over
10 years of follow-up in European, South Asian,
and African Caribbean men and women in a UK
population based cohort.
METHODS
SABRE (Southall And Brent REvisited) is a
tri-ethnic, community based cohort from Southall
and Brent (London).20 Participants aged 40–69
years at baseline (1988–1991) were randomly
selected from primary care physician lists (n=4063)
and workplaces (n=795). Ethnicity was agreed
with the interviewer based on self-report, parental
origins, and appearance. All South Asians and
African Caribbeans were migrants. South Asians
originated from the Indian subcontinent (India
90.3%, Pakistan 9.4%). Most African Caribbeans
(92.5%) originated from the Caribbean and the
remainder from West Africa.
At baseline, participants underwent fasting and
post-glucose challenge blood tests, blood pressure
measurements, ECG, anthropometry, and com-
pleted a health and lifestyle questionnaire.20
Minnesota criteria21 identiﬁed major Q waves on
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ECG. Atrial ﬁbrillation and left ventricular hypertrophy (LVH)
were identiﬁed in a subset of ECGs from European and African
Caribbean participants.20 Diabetes was determined using WHO
criteria22 or doctor diagnosed diabetes. Seated resting blood
pressure was taken as the average of two readings measured
using a random zero sphygmomanometer (Hawksley, UK).
Deaths were reported by the Ofﬁce for National Statistics.
During 2008–2011, survivors were invited to join a follow-up.
This included a health and lifestyle questionnaire and/or
primary care medical record review and/or attendance at our
clinic at St Mary’s Hospital, London. Hospital episode statistics
(HES) were obtained.
At follow-up we obtained data on family history of CHD,
deﬁned as angina or heart attack diagnosed in a parent aged
under 60 years. We assigned Townsend 2001 deprivation scores
based on output areas.4
Identiﬁcation of cardiovascular events during the ﬁrst
10 years of follow-up
We mirrored end points for QRISK2 (ﬁrst myocardial infarc-
tion, angina, CHD, stroke, transient ischaemic attack). We
included coronary revascularisation procedures as these proce-
dures incur a diagnosis of CHD on the general practice
database.
For CHD, we identiﬁed the ﬁrst event from any of the follow-
ing sources:
A. Cause of death includes International Classiﬁcation of
Disease (ICD) 9 codes 410-415 or ICD10 codes I200-I259.
B. Primary care record review.
C. Participant reported coronary revascularisation or acute
myocardial infarction.
D. HES: diagnostic ICD9 codes 410-415 or ICD10: I200-I259
or the Ofﬁce of Populations and Surveys ‘Classiﬁcation of
interventions and procedures’: K401-K469, K491-504,
K751-759 or U541.
For stroke/transient ischaemic attack, we identiﬁed the ﬁrst
event from any of the following sources:
A. Cause of death includes ICD9 codes 430-439 or ICD10
codes I600-I698
B. Primary care record review.
C. HES: diagnostic ICD9 codes 430-439 or ICD10 codes:
I600-I698.
D. Participant reported physician diagnosed stroke (duration of
symptoms >24 h).
Participants with CVD at baseline were excluded.
We performed sensitivity analyses using a stricter deﬁnition of
CHD which excluded participant reported events and uncon-
ﬁrmed angina.
All participants gave written informed consent. Approval for
the study at baseline was obtained from Ealing, Hounslow and
Spelthorne, and University College London research ethics com-
mittees, and at follow-up from St Mary’s Hospital Research
Ethics Committee (ref. 07/H0712/109).
Statistical analyses
Ten year risks of CVD events were calculated using the
Kaplan-Meier method. QRISK2 scores at baseline were calcu-
lated applying the published algorithm (http://svn.clinrisk.co.uk/
qrisk2 XML source: Q68_qrisk2_2012_1_1.xml, STATA dta
time stamp: 2 January 2012, 23:10). The Framingham risk
score was calculated using the published algorithm3 with South
Asian ethnicity adjustment.19 For primary analyses we assumed
null values for baseline data which were not available for the
majority of participants (see online supplemental table S1). We
examined ethnicity speciﬁc calibration of each score by plotting
observed against predicted risk by tenths of predicted risk and
by calculation of the Brier score (lower values indicate greater
accuracy) and the ratio of predicted to observed risk.
We assessed discrimination (differentiation of scores between
participants who did and did not experience an event) by calcu-
lating the area under the receiver operating characteristics curve
(AUROC) statistic for the end point of combined fatal and non-
fatal CVD events. In addition, we calculated the D statistic (a
measure of separation based on the ability of the prognostic
index to discriminate between participants’ risks of an event)
and R2 statistic,23 24 which estimates the proportion of
explained variance (higher values indicate better
discrimination).
We compared high (≥20%) and low risk groups for each risk
score and examined proportions of participants who would be
reclassiﬁed to a different category using the alternative risk
score and the proportion of observed events identiﬁed by high
risk classiﬁcation.
Sensitivity analyses—We repeated the above analyses recalcu-
lating QRISK2 and Framingham scores19 (a) using parental
history data, (b) using the stricter deﬁnition of CHD, and (c)
using the subset of African Caribbeans and Europeans with
baseline ECG data for deﬁnition of LVH.
All analyses were conducted in STATAV.12.
RESULTS
Of the original 4539 participants without CVD at baseline,
4228 were traceable at follow-up. Follow-up data were available
for 3821 (90%). Of measured risk factors, 89 (2.3%) partici-
pants had missing values for lipids, a Townsend score could not
be assigned to 55 addresses (1.4%), and a further three had
missing data for smoking or body mass index (BMI). Data on
chronic kidney disease were not collected at baseline; however,
only three participants had proteinuria and <5% had microal-
buminuria (table 1). Only 1% of men and no women had atrial
ﬁbrillation at baseline (subset of 1163 European and African
Caribbean participants). In the same subset, 13% had tall R
waves on ECG, suggesting LVH. No participants were receiving
statins at baseline. Assuming null values for family history,
rheumatoid arthritis, atrial ﬁbrillation, chronic kidney disease
and LVH, we were able to calculate both QRISK2 and
Framingham scores in 3674 (87% of those traced) (see online
supplemental ﬁgure S1). Our study participants had higher
Townsend scores (more deprived) than the general population
of England and Wales (table 1). Baseline characteristics of
those lost to follow-up or with missing baseline data were
similar to those included in these analyses (see online
supplemental Table S2).
Three-quarters of the participants were men, 49% were
European, 36% were South Asian, and 15% were African
Caribbean, reﬂecting the ethnicity–sex composition of the base-
line group. As expected, diabetes was more frequent in South
Asians and African Caribbeans. South Asians had less favourable
lipid proﬁles, and African Caribbeans more favourable lipid pro-
ﬁles, than Europeans. Smoking was most frequent in Europeans
(table 1).
During follow-up, 387 CVD events occurred in men (14%)
and 78 in women (8%); 82% of these were CHD events. Rates
were highest in South Asians and lowest in African Caribbeans
(ﬁgure 1).
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Table 1 Baseline characteristics (means±SD, geometric means (95% CI) or n (%))
European South Asian African Caribbean
Men
N 1359 1076 307
Age 52.8±7.1 50.8±6.9 53.5±5.8
SBP, mm Hg 123±17 125±17 128±17
Total cholesterol, mmol/L 6.0 (5.9 to 6.0) 5.8 (5.8 to 5.9) 5.5 (5.4 to 5.6)
HDL cholesterol, mmol/L 1.3 (1.2 to 1.3) 1.2 (1.1 to 1.2) 1.4 (1.3 to 1.4)
Cholesterol: HDL ratio 4.7 (4.7 to 4.8) 5.0 (5.0 to 5.1) 3.9 (3.8 to 4.1)
BMI, kg/m2 26.2±3.9 25.9±3.3 26.4±3.4
Smoking
Never 368 (27%) 811 (75%) 170 (55%)
Ex 537 (40%) 101 (9%) 58 (19%)
<10/day current 81 (6%) 53 (5%) 26 (8%)
10–19/day current 87 (6%) 65 (6%) 27 (9%)
20+/day current 3286 (21%) 46 (4%) 26 (8%)
Diabetes 81 (6%) 209 (19%) 53 (17%)
Treated hypertension 99 (7%) 136 (13%) 57 (19%)
Atrial fibrillation 2/210 (1%) – 1/170 (0.6%)
Rheumatoid arthritis n/a n/a n/a
Chronic kidney disease n/a n/a n/a
Proteinuria (AER* ≥300 mg/day) 0/813 1/599 (0.02%) 0/205
Microalbuminuria (AER* ≥30 and <300 mg/day) 27/813 (3.3%) 15/599 (2.5%) 10/205 (4.9%)
LSOA based Townsend score (Deprivation index (quintiles for England and Wales))
1 (most affluent) 65 (5%) 2 (0.2%) 0
2 44 (3%) 2 (0.2%) 2 (0.7%)
3 105 (8%) 24 (2%) 4 (1%)
4 620 (46%) 289 (27%) 75 (24%)
5 (least affluent) 525 (39%) 759 (71%) 226 (74%)
Townsend score 2.5 (2.3 to 2.6) 3.5 (3.4 to 3.7) 4.3 (4.0 to 4.6)
Family history of CHD N=688 N=554 N=152
Parents diagnosed <60 years 66 (9.6%) 33 (6.0%) 3 (2.0%)
Women
N 444 241 247
Age 53.0±6.8 50.3±6.5 52.6±6.0
SBP, mm Hg 119±16 124±20 131±17
Total cholesterol, mmol/L 6.0 (5.9 to 6.2) 5.7 (5.6 to 5.8) 5.5 (5.4 to 5.7)
HDL cholesterol, mmol/L 1.6 (1.6 to 1.7) 1.4 (1.3 to 1.4) 1.6 (1.6 to 1.7)
Cholesterol: HDL ratio 3.7 (3.6 to 3.8) 4.2 (4.0 to 4.3) 3.4 (3.3 to 3.5)
BMI, kg/m2 26.0±4.7 27.5±4.6 29.3±4.8
Smoking
Never 212 (48%) 236 (98%) 206 (83%)
Ex 100 (23%) 1 19 (8%)
<10/day current 23 (5%) 3 (1%) 7 (3%)
10–19/day current 51 (11%) 0 10 (4%)
20+/day current 58 (13%) 1 5 (2%)
Diabetes 17 (4%) 38 (16%) 53 (21%)
Treated hypertension 46 (10%) 30 (12%) 69 (28%)
LSOA based Townsend score (Deprivation index (quintiles for England and Wales))
1–2 (most affluent) 0 0 0
3 28 (6%) 1 3 (1%)
4 219 (49%) 101 (42%) 66 (26%)
5 (least affluent) 203 (45%) 143 (58%) 187 (73%)
Townsend score 3.3 (3.0 to 3.5) 3.3 (3.1 to 3.5) 4.9 (4.5 to 5.3)
Atrial fibrillation 0/249 – 0/238
Rheumatoid arthritis n/a n/a n/a
Chronic kidney disease n/a n/a n/a
Proteinuria (AER* ≥300 mg/day) 0/350 1/169 (0.06%) 0/189
Microalbuminuria (AER* ≥30 and <300 mg/day) 4/350 (1.1%) 4/169 (2.4%) 9/189 (4.8%)
Family history of CHD N=214 N=118 N=128
Parents diagnosed <60 years 24 (11.2%) 14 (11.9%) 6 (4.7%)
*AER=albumin excretion rate from timed overnight urine collections, not available in all participants.
BMI, body mass index; CHD, coronary heart disease; HDL, high density lipoprotein; LSOA, lower layer super output area; SBP, systolic blood pressure.
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Calibration
Both scores under-predicted risk in European and South Asian
women (ratio of predicted to observed risk: European women:
QRISK2 0.73, Framingham 0.73; South Asian women: QRISK2
0.52, Framingham 0.43) (table 2). Both scores more closely
approximated observed risk in European and South Asian men.
In African Caribbean men, Framingham over-predicted, while
QRISK2 showed a closer relationship with observed risk. In
African Caribbean women both scores over-predicted; however,
numbers of events were particularly small in African Caribbeans
and Brier scores for both scores suggested better calibration in
African Caribbeans (table 2, ﬁgures 1 and 2). In the subset of
survivors with parental history data, both scores still notably
under-predicted observed risk in South Asian women.
In the ECG subset, addition of LVH to the Framingham score
increased over-prediction of risk in African Caribbeans and in
European men.
Discrimination
There was little difference in the discriminative performance of
the two scores. The AUROC for men was 0.72 for both, and
the D and R2 statistics were modest at 1.20% and 25.7% for
QRISK2 and 1.22% and 26.2% for Framingham. In women,
the D and R2 statistics were 1.31% and 29.1% for QRISK2 and
1.30% and 28.7% for Framingham. Discrimination was poorest
for African Caribbeans for both scores (table 2). Repeat of dis-
crimination analyses for the subset of survivors with family
history data gave marginally better discrimination with overall
AUROC of 0.74 for both scores. The D and R2 statistics in this
subset overall were 1.30% and 28.7% (95% CI 21.0% to
36.0%) for QRISK2 and 1.34% and 30.0% (95% CI 22.3% to
37.3%) for Framingham. Addition of parental history data
improved discrimination for both scores in African Caribbeans
(AUROC: 0.75 for both scores). Addition of ECG identiﬁed
LVH did not improve discrimination for Framingham.
Classiﬁcation
One third of men (925) were classiﬁed as high risk (≥20%) by
Framingham compared with 617 (23%) men classiﬁed high risk
by QRISK2. In women, 80 (9%) (Framingham) and 66 (7%)
(QRISK2) were classiﬁed as high risk. In 683 men and women
identiﬁed by QRISK2 as high risk, 193 (28%) had CVD events
(accounting for 42% of total events). In 1025 men and women
identiﬁed by Framingham as high risk, 251 (24%) had CVD
events (accounting for 54% of total events). Reclassiﬁcation
from high risk Framingham to low risk QRISK2 would have
occurred in 354 (38%) men and 29 (36%) women.
Reclassiﬁcation from high risk QRISK2 to low risk Framingham
would have occurred in 46 (2.5%) men and 15 (1.7%) women
(see online supplemental table S3). There were pronounced
ethnic differences in classiﬁcation. Of 107 African Caribbeans
classiﬁed as high risk by Framingham, only nine experienced
events (24% of total events), while of 38 African Caribbeans
Figure 1 Observed and predicted risk over 10 years of follow-up.
Table 2 Discrimination and ratio of predicted to observed risk:
QRISK2 and Framingham risk score by sex and ethnicity (95% CIs)
QRISK2 score Framingham CVD score
Men
Europeans, n=1359
AUROC 0.70 (0.66 to 0.74) 0.71 (0.67 to 0.75)
D statistic 1.06 (0.82 to 1.30) 1.13 (0.89 to 1.36)
R2 statistic % 21.1 (13.9 to 28.6) 23.3 (15.9 to 30.8)
Brier score 0.11 (0.10 to 0.13) 0.11 (0.10 to 0.12)
Predicted: observed 0.78 (0.72 to 0.85) 0.99 (0.96 to 1.00)
South Asians, n=1076
AUROC 0.73 (0.69 to 0.77) 0.73 (0.69 to 0.77)
D statistic 1.22 (0.99 to 1.45) 1.23 (1.00 to 1.47)
R2 statistic % 26.3 (19.0 to 33.5) 26.6 (19.2 to 33.9)
Brier score 0.14 (0.12 to 0.15) 0.14 (0.12 to 0.15)
Predicted: observed 0.71 (0.64 to 0.78) 0.93 (0.88 to 0.96)
African Caribbeans, n=307
AUROC 0.67 (0.57 to 0.77) 0.63 (0.53 to 0.73)
D statistic 0.96 (0.32 to 1.59) 0.80 (0.16 to 1.43)
R2 statistic % 17.9 (2.4 to 37.6) 13.2 (0.7 to 32.8)
Brier score 0.063 (0.040 to 0.085) 0.071 (0.052 to 0.091)
Predicted: observed 0.95 (0.80 to 1.00) 1.52 (1.24 to 2.06)
All, n=2742
AUROC 0.72 (0.69 to 0.74) 0.72 (0.69 to 0.75)
D statistic 1.20 (1.04 to 1.36) 1.22 (1.06 to 1.38)
R2 statistic % 25.7 (20.6 to 30.8) 26.2 (21.1 to 31.3)
Brier score 0.12 (0.11 to 0.13) 0.12 (0.11 to 0.13)
Predicted: observed 0.75 (0.71 to 0.80) 0.99 (0.97 to 1.00)
Women
Europeans, n=444
AUROC 0.75 (0.67 to 0.82) 0.73 (0.65 to 0.80)
D statistic 1.33 (0.79 to 1.87) 1.29 (0.75 to 1.83)
R2 statistic % 29.7 (12.9 to 45.5) 28.5 (11.8 to 44.6)
Brier score 0.073 (0.046 to 0.10) 0.074 (0.053 to 0.095)
Predicted: observed 0.73 (0.57 to 0.88) 0.74 (0.57 to 0.88)
South Asians, n=241
AUROC 0.75 (0.66 to 0.84) 0.77 (0.69 to 0.86)
D statistic 1.55 (0.91 to 2.19) 1.59 (0.96 to 2.21)
R2 statistic % 36.4 (16.6 to 53.3) 37.6 (18.1 to 53.9)
Brier score 0.10 (0.063 to 0.14) 0.10 (0.073 to 0.13)
Predicted: observed 0.52 (0.34 to 0.72) 0.43 (0.25 to 0.63)
African Caribbeans, n=247
AUROC 0.65 (0.54 to 0.76) 0.62 (0.48 to 0.75)
D statistic 0.74 (0 to 1.63) 0.68 (0 to 1.58)
R2 statistic % 11.6 (0.1 to 38.9) 10.0 (0.04 to 37.2)
Brier score 0.066 (0.036 to 0.095) 0.066 (0.036 to 0.096)
Predicted: observed 1.22 (1.04 to 1.84) 1.24 (1.07 to 2.00)
All, n=932
AUROC 0.73 (0.68 to 0.78) 0.72 (0.67 to 0.78)
D statistic 1.31 (0.94 to 1.68) 1.30 (0.93 to 1.67)
R2 statistic % 29.1 (17.5 to 40.2) 28.7 (17.1 to 39.9)
Brier score 0.078 (0.060 to 0.096) 0.079 (0.061 to 0.096)
Predicted: observed 0.74 (0.63 to 84) 0.70 (0.59 to 0.80)
AUROC, area under the receiver operating characteristics curve; CVD, cardiovascular
disease.
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classiﬁed as high risk by QRISK2, only four experienced events
(10% of total events). In 30 South Asian women who experi-
enced events, QRISK2 identiﬁed 10 (33%) and Framingham
identiﬁed 13 (43%) as high risk.
A similar picture was observed for classiﬁcation in the subset
with parental history data.
Further sensitivity analyses using a stricter deﬁnition of CHD
in deﬁning the CVD outcome produced similar ﬁndings for cali-
bration, discrimination, and classiﬁcation.
DISCUSSION
In this British population based cohort, QRISK2 under-
predicted risk in South Asian and European men and women,
while Framingham under-predicted risk in South Asian women
and over-predicted in African Caribbeans. Both scores discrimi-
nated modestly between Europeans and South Asians who did
and did not experience events, but performed less well in
African Caribbeans. Using the conventional 20% threshold to
identify people at high risk of CVD events, Framingham classi-
ﬁed 50% more people as high risk than QRISK2. However,
these high risk categories predicted only 54% (Framingham)
and 42% (QRISK2) of all CVD events during 10 years of
follow-up. Classiﬁcation was particularly poor in African
Caribbeans. Using these scores to deﬁne high risk African
Caribbeans would predict less than one quarter of events. For
South Asian women, QRISK2 high risk classiﬁcation was also
poor and would have predicted only one third of events.
Inclusion of family history in risk score calculation improved
discrimination (but not calibration) properties of both scores in
African Caribbeans.
Given that the UK has large minority populations of South
Asian and African Caribbean origins, with notably different
rates of CVD compared with the European population, it is
increasingly important that prevention measures are appropri-
ately targeted.
We chose to consider the performance of QRISK2, which
includes adjustments for ethnicity and deprivation and has been
developed and tested using large UK primary care
databases.4 18 As a comparator, the Framingham 1991 score3
(incorporating NICE recommended adjustment for South Asian
men), is familiar to most physicians and, until recently, was the
risk predictor of choice according to UK national guidelines.19
We had expected QRISK2 to outperform the Framingham score
in our UK tri-ethnic population, given that the Framingham
score’s appropriateness to non-European populations with
varied socioeconomic status has been questioned.5 16 17
However, our results do not suggest clear superiority of
QRISK2 in men and women in any of the three ethnic groups.
Underestimation of risk in South Asians, particularly in women,
by both scores is of concern. The NICE ethnicity adjustment
(Framingham score x 1.4) for South Asians has been recom-
mended only for men,19 but our ﬁndings suggest that a risk
multiplier for the Framingham score might also be considered
for South Asian women and that further validation of QRISK2
Figure 2 Plots of 10 year observed
risk versus predicted risk of
cardiovascular disease (CVD) (by tenths
of predicted risk) for QRISK2 and
Framingham (with South Asian male
ethnicity adjustment) risk scores: (i)
Men; (ii) Women.
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is needed for this group. It is of note that the current Joint
British Societies 2 guidelines do not advocate a South Asian
multiplier, as it was considered that excess CHD risk in South
Asians was explained by excess diabetes.1
For clinicians, classiﬁcation to high risk categories is import-
ant in guiding implementation of preventive or therapeutic mea-
sures. The overall poor performance of the conventional
cut-point of 20% in both risk scores in predicting events is
worrying, as are the pronounced differences between the two
risk scores in classiﬁcation to high risk groups, particularly with
regard to African Caribbeans and South Asian women.
We are not aware of other validation studies of QRISK2 in
datasets beyond the QRESEARCH and THIN primary care
datasets.4 18 As is frequently observed, independent validation in
different datasets may produce results less favourable than those
of the original authors.25 This was the case for QRISK2 in our
study which demonstrated poorer discrimination than has been
reported in recent studies using primary care datasets.4 18 Our
own dataset, although small, contained few missing data,
whereas the very large derivation and validation datasets had
complete data for lipids, blood pressure, BMI, and smoking for
only 18.4% and 19.6% of women and 16% and 19% of men,
and used multiple imputation methods to overcome this.8 18
Median follow-up was 6 years in the validation study, compared
with our 10 year follow-up. These factors may contribute to the
differences in performance of QRISK2 in our study compared
with the validation studies. Surprisingly, the Framingham score,
which predicted greater levels of risk in African Caribbeans,
otherwise showed similar calibration and discrimination to
QRISK2. However, our city dwelling study population was
more deprived in terms of Townsend scores than the general
population of England and Wales and, by design, included a
large proportion of South Asians, who are known to be at high
risk of CVD. Since the Framingham score does not include any
socioeconomic adjustments, and has been reported to over-
predict risk in comparison with QRISK2, it may serendipitously
perform better in Europeans and South Asian men in this
cohort, given previous reports of over-prediction of risk in more
afﬂuent populations and under-prediction in high risk
groups.16 17
A recent UK study compared QRISK2 and Framingham scores
in association with national prevalence data in a UK black popu-
lation and found, like us, that Framingham overestimated risk in
black African Caribbeans, while QRISK2 performed better.26
Figure 2 (Continued)
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Strengths and limitations
To our knowledge this is the largest British multi-ethnic cohort
with lengthy follow-up, extensive risk factors measured in
mid-life, and only modest attrition for CVD outcomes. We did
not have complete baseline data regarding LVH or atrial ﬁbrilla-
tion, nor data on rheumatoid arthritis or chronic kidney disease.
However, our data suggest that it is likely that only a few people
in any ethnic group would have had chronic kidney disease at
baseline and that <1% had atrial ﬁbrillation. This is in keeping
with data from derivation and validation studies for QRISK and
QRISK2,4 18 which showed that <1% had rheumatoid arthritis,
and chronic kidney disease was present in <0.17%; hence,
absence of these data is unlikely to affect our ﬁndings. Numbers
of participants and CVD events are very small in women and in
African Caribbean men and we urge caution in interpreting
ﬁndings in these groups. Our main analyses assume null values
for family history; however, ﬁndings in the subset of survivors
who had parental history data collected at follow-up were
similar to those observed in the main dataset. We also acknow-
ledge that censoring due to non-CVD related deaths (n=86)
may affect our ﬁndings. Our study baseline measurements were
made over 20 years ago and the population characteristics for
each ethnic group may have changed. We compared ﬁndings
from the Health Survey for England’s (HSE) ethnic minority
study in 2004, where, for example, the prevalence of diabetes in
black Caribbean men was 5.3% in 35- to 54-year-olds and
24.8% in those aged 55+, which compares reasonably with
prevalence of 17% in our group (mean age 53.5±5.8 years).
For South Asian men, the corresponding HSE prevalences were
8.1% and 24.3% compared with 19% in our study group (mean
age 50.8±6.9 years).27 It is also likely that our ﬁndings in ﬁrst
generation migrants may not be generalisable to future genera-
tions in each ethnic minority group.
CONCLUSION
Over 10 years of follow-up in a UK population based cohort,
QRISK2 and Framingham discriminated for CVD outcomes
equivalently and modestly in European men and women and in
South Asian men. Framingham over-predicted CVD events in
African Caribbeans and both scores under-predicted in South
Asian women. Classiﬁcation to high risk groups differed notably
between the two scores; neither high risk group performed well
in predicting actual CVD events. Further validation of QRISK2
in other multi-ethnic datasets may be required. Particular atten-
tion should focus on identifying high risk African Caribbeans
and South Asian women.
Key messages
What is already known about this subject
▸ Cardiovascular risk prediction is a cornerstone of preventive
strategies.
▸ Until recently, UK national guidelines recommended the use
of the Framingham score with an ethnicity related multiplier
of 1.4 for South Asian men. More recently the QRISK2 risk
score has been developed from UK primary care data and
incorporates adjustments for ethnicity and socioeconomic
position. QRISK2 has undergone internal and external
validation in two general practice datasets, but its
performance in ethnic minorities has not been reported
separately.
How might this impact on clinical practice
▸ South Asians are at greatly elevated risk of both CHD and
stroke, while in the UK African Caribbeans are at higher risk
of stroke but lower risk of CHD compared with white
Europeans. It is important that risk prediction scores are
valid in all ethnic groups.
What does this study add
▸ Both Framingham and QRISK2 scores performed
inconsistently across ethnic groups, particularly with regard
to identifying high risk African Caribbeans and South Asian
women in this British community based cohort. Further
independent validation is needed in other multi-ethnic
datasets and better methods of identifying high risk African
Caribbeans and South Asian women are required.
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